Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Genome wide transcriptional analysis of P. aeruginosa PAO1 response to kappa-opioid U-50,488 in poor nutrient medium


ABSTRACT: Here we examined virulence activation in Pseudomonas aeruginosa in response to the synthetic kappa opioid agonist U-50, 488 in nutrient poor media where growth conditions are limited and density dependent quorum sensing is not activated. We used a microarray to define the virulence-related genes in P. aeruginosa grown in liquid poor nutrient medium to determine the effect of kappa-opioid receptor agonist on virulence/lethal phenotype All biological samples for gene expression analysis were prepared in triplicate. P. aeruginosa MPAO1 cells collected from liquid culture at 7 hrs of growth in 1.) 0.1xTY medium containing tryptone 1 g/L and yeast extract, 0.5 g/L, or 2.) 0.1xTY+25 mM potassium phosphate buffer, pH 6.0, or 3.) 0.1xTY+200 uM U-50,488, or 4.) 0.1xTY+ 25 mM potassium phosphate buffer, pH 6.0+ 200 uM U-50,488 were used for RNA isolation. Microarray analysis was performed using Affymetrix P. aeruginosa GeneChips (Affymetrix, Santa Clara, CA) at the University of Chicago Functional Genomics Facility

ORGANISM(S): Pseudomonas aeruginosa PAO1

SUBMITTER: Olga ZABORINA 

PROVIDER: E-GEOD-29946 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

The use of fluoroquinolones in chronic otitis suppurativa.

van de Heyning P H PH   Pattyn S R SR   Valcke H D HD   van Caekenberghe D L DL   Claes J J  

Pharmaceutisch weekblad. Scientific edition 19871201


The present review covers fluoroquinolone usage in chronic otitis suppurativa (COS) in case of chronic otitis media, cholesteatoma, radical mastoid cavity infection and chronic or relapsing otitis externa. A total of six publications were included in the final evaluation. Enoxacin was effective in 35%; ciprofloxacin (five publications) was used in 82 patients with 67% effectivity in otitis externa and otitis media and 61% effectivity in radical mastoid cavity infection. No serious adverse reacti  ...[more]

Similar Datasets

2012-05-21 | GSE29946 | GEO
2011-07-26 | E-GEOD-30967 | biostudies-arrayexpress
2008-06-15 | E-GEOD-7704 | biostudies-arrayexpress
2011-10-05 | E-GEOD-29789 | biostudies-arrayexpress
2011-07-01 | E-MEXP-2812 | biostudies-arrayexpress
2008-07-09 | E-TABM-464 | biostudies-arrayexpress
2010-10-23 | E-GEOD-10065 | biostudies-arrayexpress
2011-07-27 | GSE30967 | GEO
2023-08-11 | PXD040948 | Pride
2011-09-19 | E-GEOD-23007 | biostudies-arrayexpress